Pub Date : 2022-09-26DOI: 10.29011/2576-9588.100044
{"title":"Gyre and Hoop-Neuroendocrine Tumour Small Intestine","authors":"","doi":"10.29011/2576-9588.100044","DOIUrl":"https://doi.org/10.29011/2576-9588.100044","url":null,"abstract":"","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47443066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.29011/2576-9588.100043
AM Joëlle Marivel, T. Becker, Yafeng Ma, Steven, Trieu, Callum Rogers, Anvita Verma, J. Po, S. C. Ling
ctDNA in Multiple How does Automated Magnetic Bead-Based Cell-Free DNA Extraction Compare to the Leading Silica Membrane-Based Manual Abstract Introduction : Diagnosis and monitoring of haematological malignancies rely heavily on bone marrow biopsies. Less invasive peripheral blood biopsies are an emerging alternative, involving isolation of cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA) as a source of tumour information. To date, the Qiagen QIAamp Circulating Nucleic Acid kit is considered the gold standard for cfDNA isolation. However, it is time-consuming, labour intensive and relatively costly. To move ctDNA analysis into a diagnostic setting, standardisation by partially automating cfDNA extraction is highly desirable. This study revisited cfDNA extraction in multiple myeloma, a haematological cancer potentially shedding relatively high amounts of ctDNA. Methods: Four plasma samples from three myeloma patients carrying the NRASQ61R mutation and six healthy controls were used in this study. cfDNA was isolated from plasma with the manual method, Qiagen QIAamp Circulating Nucleic Acid kit and the automated Promega RSC Maxwell ccfDNA kit. The cfDNA yields were assessed and ctDNA (NRAS) detection compared by droplet digital PCR (ddPCR). Results: Although the Promega kit was more convenient, ctDNA detection was more sensitive with the Qiagen kit. Indeed, ddPCR successfully detected low NRAS mutant load in Qiagen extracts while only high NRAS mutant load was confidently detected in Promega extracts. Conclusion: The Promega kit is easier to use and more economical, but the Qiagen kit yielded significantly higher amounts of cfDNA. Moreover, critically low patient ctDNA concentration was only detectable using the Qiagen kit. This supports the superiority of the Qiagen kit for monitoring minimal residual disease.
{"title":"Towards Diagnostic ctDNA Testing in Multiple Myeloma: How does Automated Magnetic Bead-Based Cell-Free DNA Extraction Compare to the Leading Silica Membrane-Based Manual Extraction?","authors":"AM Joëlle Marivel, T. Becker, Yafeng Ma, Steven, Trieu, Callum Rogers, Anvita Verma, J. Po, S. C. Ling","doi":"10.29011/2576-9588.100043","DOIUrl":"https://doi.org/10.29011/2576-9588.100043","url":null,"abstract":"ctDNA in Multiple How does Automated Magnetic Bead-Based Cell-Free DNA Extraction Compare to the Leading Silica Membrane-Based Manual Abstract Introduction : Diagnosis and monitoring of haematological malignancies rely heavily on bone marrow biopsies. Less invasive peripheral blood biopsies are an emerging alternative, involving isolation of cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA) as a source of tumour information. To date, the Qiagen QIAamp Circulating Nucleic Acid kit is considered the gold standard for cfDNA isolation. However, it is time-consuming, labour intensive and relatively costly. To move ctDNA analysis into a diagnostic setting, standardisation by partially automating cfDNA extraction is highly desirable. This study revisited cfDNA extraction in multiple myeloma, a haematological cancer potentially shedding relatively high amounts of ctDNA. Methods: Four plasma samples from three myeloma patients carrying the NRASQ61R mutation and six healthy controls were used in this study. cfDNA was isolated from plasma with the manual method, Qiagen QIAamp Circulating Nucleic Acid kit and the automated Promega RSC Maxwell ccfDNA kit. The cfDNA yields were assessed and ctDNA (NRAS) detection compared by droplet digital PCR (ddPCR). Results: Although the Promega kit was more convenient, ctDNA detection was more sensitive with the Qiagen kit. Indeed, ddPCR successfully detected low NRAS mutant load in Qiagen extracts while only high NRAS mutant load was confidently detected in Promega extracts. Conclusion: The Promega kit is easier to use and more economical, but the Qiagen kit yielded significantly higher amounts of cfDNA. Moreover, critically low patient ctDNA concentration was only detectable using the Qiagen kit. This supports the superiority of the Qiagen kit for monitoring minimal residual disease.","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49226236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.29011/2576-9588.100042
{"title":"Cessation of Dormancy Involves an Increase of the Expression of TGFβ1 at Protein Level in Breast Cancer","authors":"","doi":"10.29011/2576-9588.100042","DOIUrl":"https://doi.org/10.29011/2576-9588.100042","url":null,"abstract":"","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":"198 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72752756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-27DOI: 10.29011/2576-9588.100038
Zeli Gao, J. Ji, Xiaotong He
Aim: The effects of probiotics on symptoms scores, gastrointestinal hormones and oxidative stress index in constipative Irritable Bowel Syndrome (IBS-C) patients were studied-during the period of 2018. Methods: 96 patients with IBS-C who had been treated in our hospital previously. The patients in the control group (49) were treated with Mosapride, and the patients in the observation group (47) were treated with Bifidobacterium triple viable enteric-coated capsules on the basis of the control treatment. The clinical efficacy including: clinical symptoms, gastrointestinal hormones, 5-HT and oxidative stress were studied and compared between the two groups. Results: In the observation group, the clinical efficacy in 29 cases (61.70%) was markedly effective and in 15 cases (31.91%) moderately effective, in comparison the total effective rate was 93.62%in the observation group, and 79.59% in the control group (P < 0.05). After treatment, the clinical symptoms score in both two groups decreased significantly. The scores of abdominal distension, abdominal pain, defecation frequency, stool characteristics and defecation difficulty in the observation group were significantly lower than those in the control group (P < 0.05). Although the levels of 5-HT, MDA and LPO in both groups decreased significantly after treatment. The levels of 5-HT, MDA and LPO in the observation group were even lower than those in the control group (P < 0.05). Similarly, the levels of gastrointestinal hormones in both groups were improved with the respective treatments. However, the MTL level in the observation group was significant higher than that in the control group, and the levels of VIP and S were lower in the observation group than those in the control group (P < 0.05). Conclusion: Bifidobacterium triple viable capsule combined with Mosapride is more effective in the treatment of IBS-C. The combination therapy can better relieve symptoms, and further decreased gastrointestinal hormone levels and reduce oxidative stress response in IBS-C patients. It is therefore highly recommended for clinical application.
{"title":"Clinical and Experimental Study on Probiotics in the Treatment of Constipation Type Irritable Bowel Syndrome","authors":"Zeli Gao, J. Ji, Xiaotong He","doi":"10.29011/2576-9588.100038","DOIUrl":"https://doi.org/10.29011/2576-9588.100038","url":null,"abstract":"Aim: The effects of probiotics on symptoms scores, gastrointestinal hormones and oxidative stress index in constipative Irritable Bowel Syndrome (IBS-C) patients were studied-during the period of 2018. Methods: 96 patients with IBS-C who had been treated in our hospital previously. The patients in the control group (49) were treated with Mosapride, and the patients in the observation group (47) were treated with Bifidobacterium triple viable enteric-coated capsules on the basis of the control treatment. The clinical efficacy including: clinical symptoms, gastrointestinal hormones, 5-HT and oxidative stress were studied and compared between the two groups. Results: In the observation group, the clinical efficacy in 29 cases (61.70%) was markedly effective and in 15 cases (31.91%) moderately effective, in comparison the total effective rate was 93.62%in the observation group, and 79.59% in the control group (P < 0.05). After treatment, the clinical symptoms score in both two groups decreased significantly. The scores of abdominal distension, abdominal pain, defecation frequency, stool characteristics and defecation difficulty in the observation group were significantly lower than those in the control group (P < 0.05). Although the levels of 5-HT, MDA and LPO in both groups decreased significantly after treatment. The levels of 5-HT, MDA and LPO in the observation group were even lower than those in the control group (P < 0.05). Similarly, the levels of gastrointestinal hormones in both groups were improved with the respective treatments. However, the MTL level in the observation group was significant higher than that in the control group, and the levels of VIP and S were lower in the observation group than those in the control group (P < 0.05). Conclusion: Bifidobacterium triple viable capsule combined with Mosapride is more effective in the treatment of IBS-C. The combination therapy can better relieve symptoms, and further decreased gastrointestinal hormone levels and reduce oxidative stress response in IBS-C patients. It is therefore highly recommended for clinical application.","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47743310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inimary T. Toby, N. Thomas, N. Thorenoor, Debbie Spear, S. Diangelo, J. Floros
Background Acute respiratory distress syndrome (ARDS) affects approximately 190,600 patients per year in the United States, with mortality up to 45%. ARDS can occur as primary disease due to various factors (e.g. bacterial or viral pneumonia, gastric aspiration, lung contusion, toxic inhalation, and near drowning) or as secondary disease due to sepsis, pancreatitis, severe trauma, massive blood transfusion, and burn. We hypothesized that ARDS-affected individuals have patterns of variants in their physiological repertoire that can be tracked and utilized to complement clinical diagnosis and/or clinical monitoring. Methods The goals of this study were to: (1) characterize the landscape of variants within protein coding but we also studied UTR regions in ARDS using an Exome sequencing approach; (2), determine the variations in signaling pathways across ARDS; and (3) use computational approaches to explore the functional consequences of ARDS. Towards this we assessed an ARDS-affected individual in the context of unaffected individuals from the same family as well as unrelated ARDS cases, in order to elucidate underlying inheritance patterns of “private variants”. Private variants consist of variants shared by ARDS cases but not found in unaffected individuals. Results Whole exome sequencing yielded 3,516 variants represented by 2,354 genes. Of these, 128 variants were shared across all ARDS cases. Of these, there were 24 unique variants represented by 9 ARDS genes shared by the primary ARDS-case and unrelated individuals with ARDS. The overall genes identified and subsequent analysis, demonstrate that there are important biological pathways that distinguish ARDS cases from or from non-ARDS. These pathways include: cell-to-cell signaling interaction, cell growth and proliferation and cell morphology. The data also show a coordinated effort amongst biological processes such as liver hyperproliferation and cell death that underlie the pathogenesis of ARDS. Conclusions These in-silico discoveries demonstrate a role for private variants shared by ARDS cases to be leveraged as biomarkers for clinical diagnosis and/or monitoring of ARDS.
{"title":"Characterizing a Focused Landscape of Familial Acute Respiratory Distress Syndrome","authors":"Inimary T. Toby, N. Thomas, N. Thorenoor, Debbie Spear, S. Diangelo, J. Floros","doi":"10.21203/rs.2.13330/v1","DOIUrl":"https://doi.org/10.21203/rs.2.13330/v1","url":null,"abstract":"\u0000 Background Acute respiratory distress syndrome (ARDS) affects approximately 190,600 patients per year in the United States, with mortality up to 45%. ARDS can occur as primary disease due to various factors (e.g. bacterial or viral pneumonia, gastric aspiration, lung contusion, toxic inhalation, and near drowning) or as secondary disease due to sepsis, pancreatitis, severe trauma, massive blood transfusion, and burn. We hypothesized that ARDS-affected individuals have patterns of variants in their physiological repertoire that can be tracked and utilized to complement clinical diagnosis and/or clinical monitoring. Methods The goals of this study were to: (1) characterize the landscape of variants within protein coding but we also studied UTR regions in ARDS using an Exome sequencing approach; (2), determine the variations in signaling pathways across ARDS; and (3) use computational approaches to explore the functional consequences of ARDS. Towards this we assessed an ARDS-affected individual in the context of unaffected individuals from the same family as well as unrelated ARDS cases, in order to elucidate underlying inheritance patterns of “private variants”. Private variants consist of variants shared by ARDS cases but not found in unaffected individuals. Results Whole exome sequencing yielded 3,516 variants represented by 2,354 genes. Of these, 128 variants were shared across all ARDS cases. Of these, there were 24 unique variants represented by 9 ARDS genes shared by the primary ARDS-case and unrelated individuals with ARDS. The overall genes identified and subsequent analysis, demonstrate that there are important biological pathways that distinguish ARDS cases from or from non-ARDS. These pathways include: cell-to-cell signaling interaction, cell growth and proliferation and cell morphology. The data also show a coordinated effort amongst biological processes such as liver hyperproliferation and cell death that underlie the pathogenesis of ARDS. Conclusions These in-silico discoveries demonstrate a role for private variants shared by ARDS cases to be leveraged as biomarkers for clinical diagnosis and/or monitoring of ARDS.","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47466207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.29011/2576-9588.100032
Abdulina Galiya, A. Saule, N. Antonina, Lavrinenko Аlena, S. Nataliya
Introduction: Recent studies show that 85% of cases of non-traumatic amputations in patients with diabetes mellitus are preceded by a wound infection of the foot, this confirms the need for rational antimicrobial therapy. Therefore, competent rapid identification of microorganisms is a priority task of modern microbiology. Matrix-Assisted Laser Desorption Ionization TOFstands for Time of Flight Mass Spectrometry (MALDI-TOF MS) is considered as the revolution in bacteriology, to identify pathogens isolated in a clinical microbiological laboratory. In this regard, MALDI-TOF MS is an ideal solution for the rapid identification of DFS Objectives: To Explore of Modern Laboratory Technique (MALDI-TOF MS) for the identification of opportunistic microorganisms in patients with Diabetic Foot Syndrome (DFS). Materials and Methods: Was performed from September 2012 to May 2015 on patients admitted to the Emergency Room of the Hospital General de México. 72 patients with (DFS) diabetic foot syndrome were investigated for the period of 2013-2015 years. The comparison group consisted of 30 patients with chronic purulent inflammatory diseases of the lower extremities not suffering from diabetes mellitus. Identification of microorganisms was carried out using MALDI-TOF spectrometry (BRUKER 2012). Results: This study revealed the prevalence gram-positive bacteria in patients with DFS. The dominant microorganism in the etiology of DFS was S. aureus, which occurred mostly as monoculture. Coagulase-Negative Staphylococci (CoNS) were represented mainly by S. haemolyticus and S. epidermidis generally recognized as a pathogen of medical devices in our case does not have an important role. Enterobacteria and non-fermenting bacteria represented Gram-negative bacteria. DOI: 10.29011/2576-9588.100032
{"title":"Opportunistic Microorganisms Identification Using a Modern Laboratory Technique","authors":"Abdulina Galiya, A. Saule, N. Antonina, Lavrinenko Аlena, S. Nataliya","doi":"10.29011/2576-9588.100032","DOIUrl":"https://doi.org/10.29011/2576-9588.100032","url":null,"abstract":"Introduction: Recent studies show that 85% of cases of non-traumatic amputations in patients with diabetes mellitus are preceded by a wound infection of the foot, this confirms the need for rational antimicrobial therapy. Therefore, competent rapid identification of microorganisms is a priority task of modern microbiology. Matrix-Assisted Laser Desorption Ionization TOFstands for Time of Flight Mass Spectrometry (MALDI-TOF MS) is considered as the revolution in bacteriology, to identify pathogens isolated in a clinical microbiological laboratory. In this regard, MALDI-TOF MS is an ideal solution for the rapid identification of DFS Objectives: To Explore of Modern Laboratory Technique (MALDI-TOF MS) for the identification of opportunistic microorganisms in patients with Diabetic Foot Syndrome (DFS). Materials and Methods: Was performed from September 2012 to May 2015 on patients admitted to the Emergency Room of the Hospital General de México. 72 patients with (DFS) diabetic foot syndrome were investigated for the period of 2013-2015 years. The comparison group consisted of 30 patients with chronic purulent inflammatory diseases of the lower extremities not suffering from diabetes mellitus. Identification of microorganisms was carried out using MALDI-TOF spectrometry (BRUKER 2012). Results: This study revealed the prevalence gram-positive bacteria in patients with DFS. The dominant microorganism in the etiology of DFS was S. aureus, which occurred mostly as monoculture. Coagulase-Negative Staphylococci (CoNS) were represented mainly by S. haemolyticus and S. epidermidis generally recognized as a pathogen of medical devices in our case does not have an important role. Enterobacteria and non-fermenting bacteria represented Gram-negative bacteria. DOI: 10.29011/2576-9588.100032","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69469900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.29011/2576-9588.100035
A. Ji, D. Rat, Stéphane Muccio, Alexandra Tavernier, L. Taylor, L. L. Chung, S. Richards
Pyoverdines and pyochelin are siderophore compounds secreted by Pseudomonas aeruginosa present in cystic fibrosis affected patients. The available literature on the quantification of pyoverdines and pyochelin in sputa of cystic fibrosis patients is based on detecting the fluorescence properties of the targets detecting pyoverdines and pyochelin without differentiating the types by chromagraphic separation. Within these studies pyochelin was always far less detected than pyoverdines. This is in contrast to gene expression data and suggets the pyochelin fluorescence detection method lacks sensitivity which results in the molecule being non-detectable. In this report, we describe a novel and sensitive LC/MS/MS method for quantitation of pyochelin in human sputum from cystic fibrosis affected patients with Pseudomonas aeruginosa (culture positive) infection. Using a validated bioanalytical method, 26 sputum samples from cystic fibrosis patients from a biobank were analyzed. Data showed the LC/MS/MS method met bioanalytical validation acceptance criteria and results of pyochelin were consistent with reported results of Pseudomonas aeruginosa concentration in cystic fibrosis patients. This new approach for quantitation of pyochelin in human sputum is more sensitive, reproducible and easier to reliably measure the biomarker pyochelin in cystic fibrosis patients. Monitoring pyoverdines and pyochelin in the sputum samples from cystic fibrosis patients may provide better analytical tools for cystic fibrosis new drug development. DOI: 10.29011/2576-9588.100035
{"title":"A Novel and Sensitive LC/MS/MS Method for Quantitation of Pyochelin in Human Sputum Samples from Cystic Fibrosis Patients","authors":"A. Ji, D. Rat, Stéphane Muccio, Alexandra Tavernier, L. Taylor, L. L. Chung, S. Richards","doi":"10.29011/2576-9588.100035","DOIUrl":"https://doi.org/10.29011/2576-9588.100035","url":null,"abstract":"Pyoverdines and pyochelin are siderophore compounds secreted by Pseudomonas aeruginosa present in cystic fibrosis affected patients. The available literature on the quantification of pyoverdines and pyochelin in sputa of cystic fibrosis patients is based on detecting the fluorescence properties of the targets detecting pyoverdines and pyochelin without differentiating the types by chromagraphic separation. Within these studies pyochelin was always far less detected than pyoverdines. This is in contrast to gene expression data and suggets the pyochelin fluorescence detection method lacks sensitivity which results in the molecule being non-detectable. In this report, we describe a novel and sensitive LC/MS/MS method for quantitation of pyochelin in human sputum from cystic fibrosis affected patients with Pseudomonas aeruginosa (culture positive) infection. Using a validated bioanalytical method, 26 sputum samples from cystic fibrosis patients from a biobank were analyzed. Data showed the LC/MS/MS method met bioanalytical validation acceptance criteria and results of pyochelin were consistent with reported results of Pseudomonas aeruginosa concentration in cystic fibrosis patients. This new approach for quantitation of pyochelin in human sputum is more sensitive, reproducible and easier to reliably measure the biomarker pyochelin in cystic fibrosis patients. Monitoring pyoverdines and pyochelin in the sputum samples from cystic fibrosis patients may provide better analytical tools for cystic fibrosis new drug development. DOI: 10.29011/2576-9588.100035","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69470166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-25DOI: 10.29011/2576-9588.100029
M. Trivedi, S. Jana
Author(s): Trivedi, Mahendra Kumar; Jana, Snehasis | Abstract: The present study was performed to investigate the Hepatoprotective potential of the Biofield Energy (The Trivedi Effect®) Treated test item, Dulbecco’s Modified Eagle Medium (DMEM) in HepG2 cells. The test item was distributed into two parts. One part received Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the Biofield Energy Treated DMEM group and the other part referred as the untreated DMEM group, where no Biofield Treatment was provided. Results showed that more than 97% cell viability of the test items were observed by MTT assay, which indicated a safe and nontoxic nature of the test items. The Biofield Treated DMEM showed significant (p≤0.001) protection of cells by 10% against oxidative stress induced by t-BHP, while the untreated DMEM group showed 0.4% protection. The level of interleukin-8 (IL-8) was significantly (p≤0.01) reduced by 31.57% in Biofield Treated DMEM than untreated DMEM. The level of ALT enzyme activity was significantly (p≤0.001) reduced by 66% in Biofield Treated DMEM compared to untreated DMEM. Cholesterol level was significantly (p≤0.001) reduced by 46.23% in Biofield Treated DMEM than untreated DMEM. Besides, Biofield Treated DMEM group showed 51.18% increased the level of albumin compared to untreated DMEM group. Overall, results demonstrated that Biofield Treatment significantly protect the liver hepatocytes against oxidative stress. Therefore, Consciousness Energy Healing (The Trivedi Effect®) Treatment might be useful as a hepatoprotectant against different types of liver injuries like cirrhosis, alcohol abuse, hemochromatosis, Wilson’s disease, Gilbert’s disease, cholangiocarcinoma, steatosis, Budd-Chiari syndrome, etc.
{"title":"Hepatoprotective Effect of Biofield Energy Treatment On Tert-Butyl Hydro Peroxide Induced Liver Injury in Hepatocellular Carcinoma Cell Line (HepG2)","authors":"M. Trivedi, S. Jana","doi":"10.29011/2576-9588.100029","DOIUrl":"https://doi.org/10.29011/2576-9588.100029","url":null,"abstract":"Author(s): Trivedi, Mahendra Kumar; Jana, Snehasis | Abstract: The present study was performed to investigate the Hepatoprotective potential of the Biofield Energy (The Trivedi Effect®) Treated test item, Dulbecco’s Modified Eagle Medium (DMEM) in HepG2 cells. The test item was distributed into two parts. One part received Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the Biofield Energy Treated DMEM group and the other part referred as the untreated DMEM group, where no Biofield Treatment was provided. Results showed that more than 97% cell viability of the test items were observed by MTT assay, which indicated a safe and nontoxic nature of the test items. The Biofield Treated DMEM showed significant (p≤0.001) protection of cells by 10% against oxidative stress induced by t-BHP, while the untreated DMEM group showed 0.4% protection. The level of interleukin-8 (IL-8) was significantly (p≤0.01) reduced by 31.57% in Biofield Treated DMEM than untreated DMEM. The level of ALT enzyme activity was significantly (p≤0.001) reduced by 66% in Biofield Treated DMEM compared to untreated DMEM. Cholesterol level was significantly (p≤0.001) reduced by 46.23% in Biofield Treated DMEM than untreated DMEM. Besides, Biofield Treated DMEM group showed 51.18% increased the level of albumin compared to untreated DMEM group. Overall, results demonstrated that Biofield Treatment significantly protect the liver hepatocytes against oxidative stress. Therefore, Consciousness Energy Healing (The Trivedi Effect®) Treatment might be useful as a hepatoprotectant against different types of liver injuries like cirrhosis, alcohol abuse, hemochromatosis, Wilson’s disease, Gilbert’s disease, cholangiocarcinoma, steatosis, Budd-Chiari syndrome, etc.","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44342003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-12DOI: 10.29011/2576-9588.100028
K. Matlho, X. Wang, Viviane Conceição, Suneth S. Perera, Bin Wang, Maly Soedjono, Ma Jin Min, N. Saksena
Monocytes are phenotypically pliable, which allows them to play several significant immunological roles in combating HIV infection. Monocytes can be subcategorized into subsets based on the expression of CD14 and CD16 antigens. Although the CD4+ T cell counts have been shown to predict HIV viremia, the actual predictive value of these monocyte subsets at different stages of plasma viremia is not known. We derived ex-vivo monocytes from HIV+ patients with detectable and below detectable plasma viremia, HIV+ Long-Term Non-Progressors (LTNP) and HIV negative individuals. We subdivided monocytes into CD14+/ CD16-low, medium and high populations and visualized the phenotypic changes in expression of both CD14 and CD16 antigens in HIV+ patients at different stages of HIV disease. The expression of surface markers on monocytes (CD14+/CD16) was measured from the EDTA blood of 50 HIV+ individuals [14 viremic and 29 Below Detectable Level (BDL) whilst on HAART, 7 therapy naïve, aviremic LTNP’s] and 6 HIVnegative donors using the FACSCanto (6-color) flow cytometer. Percentage of CD16/CD14+ sub-populations were measured on FACSCantoA with FACSDiva (v 6.1.2) software and analysed by FlowJo software (v10.0.7), respectively. By categorizing monocyte population into CD14+, CD16 high, medium and low, we could clearly discriminate between viremic and aviremic HIV patients. There was considerable elevation of CD16-low population (80%) in HIV-negative individuals and LTNPS (57%), as opposed to 9% in HAART-treated group. Noteworthy was the CD16-low population failed to recover despite complete viral control during HAART therapy suggesting their definitive role as indicators of viremic control as seen with their marked prominence in LTNPs. In contrast, the HAART-treated group showed elevated CD16-high populations (34%), as opposed to relatively low percentages in the viremic group (3%). The robust maintenance and elevation of CD16-low populations and substantial low levels of CD16-high populations distinctively in HIV-negative and non-progressing HIV+ individuals correlated with the natural control of HIV in LTNPs. This feature of CD16-low monocytic population can be exploited as a biomarker in predicting plasma viremia and the strength of the immune system. DOI: 10.29011/2576-9588. 100028
{"title":"CD14+CD16-Low Monocyte Subset Predicts Non-Progressive HIV Disease: Evidence of A New Prognostic and Diagnostic Biomarker","authors":"K. Matlho, X. Wang, Viviane Conceição, Suneth S. Perera, Bin Wang, Maly Soedjono, Ma Jin Min, N. Saksena","doi":"10.29011/2576-9588.100028","DOIUrl":"https://doi.org/10.29011/2576-9588.100028","url":null,"abstract":"Monocytes are phenotypically pliable, which allows them to play several significant immunological roles in combating HIV infection. Monocytes can be subcategorized into subsets based on the expression of CD14 and CD16 antigens. Although the CD4+ T cell counts have been shown to predict HIV viremia, the actual predictive value of these monocyte subsets at different stages of plasma viremia is not known. We derived ex-vivo monocytes from HIV+ patients with detectable and below detectable plasma viremia, HIV+ Long-Term Non-Progressors (LTNP) and HIV negative individuals. We subdivided monocytes into CD14+/ CD16-low, medium and high populations and visualized the phenotypic changes in expression of both CD14 and CD16 antigens in HIV+ patients at different stages of HIV disease. The expression of surface markers on monocytes (CD14+/CD16) was measured from the EDTA blood of 50 HIV+ individuals [14 viremic and 29 Below Detectable Level (BDL) whilst on HAART, 7 therapy naïve, aviremic LTNP’s] and 6 HIVnegative donors using the FACSCanto (6-color) flow cytometer. Percentage of CD16/CD14+ sub-populations were measured on FACSCantoA with FACSDiva (v 6.1.2) software and analysed by FlowJo software (v10.0.7), respectively. By categorizing monocyte population into CD14+, CD16 high, medium and low, we could clearly discriminate between viremic and aviremic HIV patients. There was considerable elevation of CD16-low population (80%) in HIV-negative individuals and LTNPS (57%), as opposed to 9% in HAART-treated group. Noteworthy was the CD16-low population failed to recover despite complete viral control during HAART therapy suggesting their definitive role as indicators of viremic control as seen with their marked prominence in LTNPs. In contrast, the HAART-treated group showed elevated CD16-high populations (34%), as opposed to relatively low percentages in the viremic group (3%). The robust maintenance and elevation of CD16-low populations and substantial low levels of CD16-high populations distinctively in HIV-negative and non-progressing HIV+ individuals correlated with the natural control of HIV in LTNPs. This feature of CD16-low monocytic population can be exploited as a biomarker in predicting plasma viremia and the strength of the immune system. DOI: 10.29011/2576-9588. 100028","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47049294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-22DOI: 10.29011/2576-9588.100027
T. Smith‐Norowitz, Yitzchok M. Norowitz, Tehila A. Saadia, Natalie Banniettis, H. Durkin, S. Kohlhoff
Hepatitis B virus (HBV) is a public health concern; introduction of the HBV vaccine has reduced rates of primary infection. However, some vaccinated subjects do not produce protective antibody (Ab) levels detectable by commercial assays, while others may lose detectable Abs after vaccination. Absence of HBV Ab responses after vaccination has been less studied in patients with asthma, who may be at increased risk of infection. In this case study we describe IgG-and IgE-HBV Ab levels in two patients: an asthmatic and a non-asthmatic control, pre and post HBV re-immunization. It is unknown how specific HBV IgE and B cell memory responses relate to protective immunity compared with IgG titer levels. We report that baseline HBV IgG Ab levels were negative in the asthma and non-asthma subjects, who were previously vaccinated with HBV vaccine. After re-immunization we observed that HBV IgG Ab levels in the asthma patient were positive, and then reverted back to negative; in non-asthma HBV IgG levels were positive, and then reverted back to negative. Baseline HBV IgE Ab levels were low in asthma, but were high in non-asthma. After re-immunization, HBV IgE Ab levels in asthma were detected then remained low. However, HBV IgE Ab levels remained high in non-asthma at each time point. Thus, (1) vaccination with HBV vaccine boosts IgG HBV responses, and to a lesser extent IgE responses and (2) vaccine induced measureable IgGand IgEHBV Ab responses are lower in asthma than non-asthma. Specific IgGand IgEHBV Ab responses are important factors for maintenance of sustained HBV Ab expression after HBV vaccination, and may contribute to regulation of immune responses. DOI: 10.29011/2576-9588. 100027
{"title":"Negative IgG and IgE Hepatitis B Virus Antibody Status in Asthma: A Case Study","authors":"T. Smith‐Norowitz, Yitzchok M. Norowitz, Tehila A. Saadia, Natalie Banniettis, H. Durkin, S. Kohlhoff","doi":"10.29011/2576-9588.100027","DOIUrl":"https://doi.org/10.29011/2576-9588.100027","url":null,"abstract":"Hepatitis B virus (HBV) is a public health concern; introduction of the HBV vaccine has reduced rates of primary infection. However, some vaccinated subjects do not produce protective antibody (Ab) levels detectable by commercial assays, while others may lose detectable Abs after vaccination. Absence of HBV Ab responses after vaccination has been less studied in patients with asthma, who may be at increased risk of infection. In this case study we describe IgG-and IgE-HBV Ab levels in two patients: an asthmatic and a non-asthmatic control, pre and post HBV re-immunization. It is unknown how specific HBV IgE and B cell memory responses relate to protective immunity compared with IgG titer levels. We report that baseline HBV IgG Ab levels were negative in the asthma and non-asthma subjects, who were previously vaccinated with HBV vaccine. After re-immunization we observed that HBV IgG Ab levels in the asthma patient were positive, and then reverted back to negative; in non-asthma HBV IgG levels were positive, and then reverted back to negative. Baseline HBV IgE Ab levels were low in asthma, but were high in non-asthma. After re-immunization, HBV IgE Ab levels in asthma were detected then remained low. However, HBV IgE Ab levels remained high in non-asthma at each time point. Thus, (1) vaccination with HBV vaccine boosts IgG HBV responses, and to a lesser extent IgE responses and (2) vaccine induced measureable IgGand IgEHBV Ab responses are lower in asthma than non-asthma. Specific IgGand IgEHBV Ab responses are important factors for maintenance of sustained HBV Ab expression after HBV vaccination, and may contribute to regulation of immune responses. DOI: 10.29011/2576-9588. 100027","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41399765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：